Innoviva Price to Sales Ratio 2012-2026 | INVA
Historical PS ratio values for Innoviva (INVA) over the last 10 years. The current P/S ratio for Innoviva as of June 16, 2026 is .
| Innoviva P/S Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Sales per Share | Price to Sales Ratio |
| 2026-06-17 | 22.64 | 4.57 | |
| 2026-03-31 | 23.30 | $4.96 | 4.70 |
| 2025-12-31 | 19.99 | $5.21 | 3.83 |
| 2025-09-30 | 18.25 | $5.11 | 3.57 |
| 2025-06-30 | 20.09 | $5.26 | 3.82 |
| 2025-03-31 | 18.13 | $5.67 | 3.20 |
| 2024-12-31 | 17.35 | $5.17 | 3.35 |
| 2024-09-30 | 19.31 | $4.92 | 3.92 |
| 2024-06-30 | 16.40 | $4.28 | 3.83 |
| 2024-03-31 | 15.24 | $3.92 | 3.89 |
| 2023-12-31 | 16.04 | $3.86 | 4.16 |
| 2023-09-30 | 12.99 | $3.56 | 3.65 |
| 2023-06-30 | 12.73 | $3.48 | 3.66 |
| 2023-03-31 | 11.25 | $3.37 | 3.33 |
| 2022-12-31 | 13.25 | $3.48 | 3.80 |
| 2022-09-30 | 11.61 | $3.94 | 2.95 |
| 2022-06-30 | 14.76 | $4.43 | 3.33 |
| 2022-03-31 | 19.35 | $4.30 | 4.50 |
| 2021-12-31 | 17.25 | $4.09 | 4.21 |
| 2021-09-30 | 16.71 | $3.75 | 4.46 |
| 2021-06-30 | 13.41 | $3.33 | 4.02 |
| 2021-03-31 | 11.95 | $3.03 | 3.95 |
| 2020-12-31 | 12.39 | $2.97 | 4.18 |
| 2020-09-30 | 10.45 | $2.84 | 3.68 |
| 2020-06-30 | 13.98 | $2.64 | 5.30 |
| 2020-03-31 | 11.76 | $2.51 | 4.69 |
| 2019-12-31 | 14.16 | $2.30 | 6.15 |
| 2019-09-30 | 10.54 | $2.34 | 4.51 |
| 2019-06-30 | 14.56 | $2.30 | 6.33 |
| 2019-03-31 | 14.03 | $2.33 | 6.03 |
| 2018-12-31 | 17.45 | $2.30 | 7.58 |
| 2018-09-30 | 15.24 | $2.18 | 7.00 |
| 2018-06-30 | 13.80 | $2.04 | 6.77 |
| 2018-03-31 | 16.67 | $1.93 | 8.62 |
| 2017-12-31 | 14.19 | $1.81 | 7.85 |
| 2017-09-30 | 14.12 | $1.58 | 8.92 |
| 2017-06-30 | 12.80 | $1.45 | 8.83 |
| 2017-03-31 | 13.83 | $1.22 | 11.29 |
| 2016-12-31 | 10.70 | $1.10 | 9.71 |
| 2016-09-30 | 10.99 | $0.95 | 11.62 |
| 2016-06-30 | 10.53 | $0.79 | 13.33 |
| 2016-03-31 | 12.59 | $0.62 | 20.27 |
| 2015-12-31 | 10.54 | $0.47 | 22.54 |
| 2015-09-30 | 7.18 | $0.33 | 21.46 |
| 2015-06-30 | 17.74 | $0.23 | 78.36 |
| 2015-03-31 | 15.21 | $0.14 | 106.87 |
| 2014-12-31 | 13.52 | $0.08 | 180.05 |
| 2014-09-30 | 16.04 | $0.02 | 659.80 |
| 2014-06-30 | 27.65 | $0.02 | 1426.02 |
| 2014-03-31 | 23.15 | $0.02 | 944.11 |
| 2013-12-31 | 26.67 | $0.05 | 585.35 |
| 2013-09-30 | 30.57 | $0.09 | 332.56 |
| 2013-06-30 | 28.82 | $0.10 | 279.62 |
| 2013-03-31 | 17.67 | $0.11 | 167.37 |
| 2012-12-31 | 16.64 | $1.47 | 11.30 |
| 2012-09-30 | 19.38 | $1.48 | 13.13 |
| 2012-06-30 | 16.62 | $1.54 | 10.80 |
| 2012-03-31 | 14.59 | $1.60 | 9.11 |
| 2011-12-31 | 16.53 | $0.30 | 55.16 |
| 2011-09-30 | 15.07 | $0.33 | 45.56 |
| 2011-06-30 | 16.61 | $0.32 | 51.18 |
| 2011-03-31 | 18.12 | $0.33 | 54.57 |
| 2010-12-31 | 18.75 | $0.34 | 54.88 |
| 2010-09-30 | 15.04 | $0.31 | 49.13 |
| 2010-06-30 | 9.40 | $0.32 | 29.26 |
| 2010-03-31 | 9.96 | $0.32 | 30.82 |
| 2009-12-31 | 9.78 | $0.39 | 25.17 |
| 2009-09-30 | 10.95 | $0.42 | 25.79 |
| 2009-06-30 | 10.95 | $0.43 | 25.18 |
| 2009-03-31 | 12.72 | $0.44 | 29.07 |
| 2008-12-31 | 9.27 | $0.38 | 24.60 |
| 2008-09-30 | 9.32 | $0.37 | 24.99 |
| 2008-06-30 | 8.88 | $0.37 | 24.06 |
| 2008-03-31 | 7.88 | $0.37 | 21.47 |
| 2007-12-31 | 14.59 | $0.36 | 40.04 |
| 2007-09-30 | 19.52 | $0.35 | 55.01 |
| 2007-06-30 | 23.94 | $0.35 | 67.67 |
| 2007-03-31 | 22.07 | $0.35 | 63.56 |
| 2006-12-31 | 23.11 | $0.33 | 69.42 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $1.760B | $0.411B |
| Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |